NEW INDICATION
COVID-19 has become a major public health challenge around the world. We know that you, and your patients, are looking for answers. The American Society of Hematology (ASH) has put together a series of FREQUENTLY ASKED QUESTIONS to provide certain relevant information surrounding this novel virus and the hematologic conditions you treat.
REVOLADE is indicated for the treatment of:
References:
1. REVOLADE Summary of Product Characteristics. February 2019. 2. Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(3):2527-2536.
You are now leaving the REVOLADE.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.
You are now leaving the REVOLADE.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.